Plain-English translation of NCT07519486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether intensive nutritional support — delivered through special oral nutrition drinks and careful dietary guidance — can help patients with locally advanced esophageal squamous cell carcinoma better tolerate treatment and improve their chances of a complete response to therapy. You would receive this treatment alongside a combination of immunotherapy medication (a PD-1 inhibitor) and chemotherapy, followed by surgery.
Many patients with advanced esophageal cancer become malnourished, which can weaken their immune system and make it harder for them to tolerate intensive treatments. Researchers want to see if keeping patients better nourished during therapy can improve treatment effectiveness and help their bodies fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to either the intensive nutrition support group or the standard care group. Both groups receive the same immunotherapy and chemotherapy treatment. The intensive nutrition group will receive specially formulated oral nutrition supplements and personalized dietary guidance to optimize your nutritional status throughout treatment. After completing the medical therapy, you will undergo surgery as planned. You'll have regular clinic visits and blood tests to monitor your health, nutrition status, and how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China